Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells

Journal of Virology

Volumn 76, Issue 10, 2002, Pages 4810-4821

  Mascola, John R ^a   Louder, Mark K ^a   Winter, Christine ^a   Prabhakara, Ranjani ^a   De Rosa, Stephen C ^a   Douek, Daniel C ^a   Hill, Brenna J ^a   Gabuzda, Dana ^a   Roederer, Mario ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; GAG PROTEIN; PROTEINASE INHIBITOR;

ACCURACY; ANTIBODY RESPONSE; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; DILUTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; T LYMPHOCYTE; VIRUS INACTIVATION; VIRUS NEUTRALIZATION;

CELLS, CULTURED; FLOW CYTOMETRY; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; NEUTRALIZATION TESTS; PREDICTIVE VALUE OF TESTS; PROTEASE INHIBITORS; T-LYMPHOCYTES;

EID: 0036237167     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.10.4810-4821.2002     Document Type: Article

References (78)

1. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera
2. Observations on anti-phage-1: The percentage lab
3. Neutralizing antibody response during human immunodeficiency virus type 1 infection: Type and group specificity and viral escape
4. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection
5. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
6. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease
7. Immunization with recombinant canarypox vectors expressing membraneanchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
8. A caution on the use of SIV/HIV gag antigen detection systems in neutralization assays
9. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage
10. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses
11. Biologic features of HIV-1 that correlate with virulence in the host
12. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity
13. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes
14. Detection of human immunodeficiency virus-infected lymphoid cells at low frequency by flow cytometry
15. Detection of circulating p24 antigen-positive CD4+ cells during HIV infection by flow cytometry
16. A flow cytometric method for measuring neutralization of HIV-1 subtype B and E primary isolates
17. A study of the basic aspects of neutralization of two animal viruses, Western equine encephalitis virus and poliomyelitis virus
18. A multi-hit model for the neutralization of animal viruses
19. Neutralization of animal viruses
20. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution
21. Replicative capacity, cytopathic effect and cell tropism of HIV
22. Development of a flow cytometric assay for the detection and measurement of neutralizing antibodies against human immunodeficiency virus
23. Biological and biochemical characterization of a cloned Leu-3-cell surviving infection with the acquired immune deficiency syndrome retrovirus
24. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
25. A new reporter cell line to monitor HIV infection and drug susceptibility in vitro
26. CD4 down-modulation by human immunodeficiency virus type 1 Nef correlates with the efficiency of viral replication and with CD4(+) T-cell depletion in human lymphoid tissue ex vivo
27. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia
28. Use of a novel human immunodeficiency virus type 1 reporter virus expressing human placental alkaline phosphatase to detect an alternative viral receptor
29. Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants
30. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins
31. Increased expression of CD80 and CD86 in in vitro-infected CD3+ cells producing cytoplasmic HIV type 1 p24
32. Antibodies to p24 antigen do not specifically detect HIV-infected lymphocytes in AIDS patients
33. Importance of membrane fusion mediated by human immunodeficiency virus envelope glycoproteins for lysis of primary CD4-positive T cells
34. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185
35. Neutralization of animal viruses
36. Neutralization of HIV-1 infection of human peripheral blood mononuclear cells: Antibody dilution method
37. Antigen detection in neutralization assays: High levels of interfering anti-p24 antibodies in some plasma
38. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
39. Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay
40. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12
41. Two antigenically distinct subtypes of human immunodeficiency virus type 1: Viral genotype predicts neutralization serotype
42. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
43. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
44. Detection and quantitation of human immunodeficiency virus-infected peripheral blood mononuclear cells by flow cytometry
45. Differential representations of memory T cell subsets are characteristic of polarized immunity in leprosy and atopic diseases
46. Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus
47. Quantitative infectivity assay for HIV-1 and -2
48. Simple, rapid, quantitative, syncytiumforming microassay for the detection of human immunodeficiency virus neutralizing antibody
49. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding
50. Use of a green fluorescent protein as a marker for human immunodeficiency virus type 1 infection
51. The physico-chemical factors that govern retrovirus-mediated gene transfer
52. The antiviral activity of antibodies in vitro and in vivo
53. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro
54. Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120
55. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5
56. HIV neutralization assay using polymerase chain reaction-derived molecular signals
57. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex
58. LuSIV cells: A reporter cell line for the detection and quantitation of a single cycle of HIV and SIV replication
59. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120
60. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated
61. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture
62. Rapidly and slowly replicating human immunodeficiency virus type 1 isolates can be distinguished according to target-cell tropism in T-cell and monocyte cell lines
63. Separable mechanisms of attachment and cell uptake during retrovirus infection
64. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
65. A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1
66. Viral multiplicity of attachment and its implications for human immunodeficiency virus therapies
67. Flow cytometric analysis of virus-infected cells and its potential use for screening antiviral agents
68. Neuraminidase from a bacterial source enhances both HIV-1-mediated syncytium formation and the virus binding/entry process
69. Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics
70. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: Studies on sequential HIV isolates
71. Human immunodeficiency virus infection studied in CD4-expressing human-murine T-cell hybrids
72. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
73. Modeling HIV transfer between dendritic cells and T cells: Importance of HIV phenotype, dendritic cell-T cell contact and T-cell activation
74. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses
75. Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease
76. International collaborative study to compare assays for antibodies that neutralize human immunodeficiency virus
77. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients
78. Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry